Etoposide

Generic Name
Etoposide
Brand Names
Etopophos, Toposar, Vepesid
Drug Type
Small Molecule
Chemical Formula
C29H32O13
CAS Number
33419-42-0
Unique Ingredient Identifier
6PLQ3CP4P3
Background

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

First Posted Date
2018-10-25
Last Posted Date
2023-10-26
Lead Sponsor
New York Medical College
Target Recruit Count
40
Registration Number
NCT03719105
Locations
🇺🇸

Children's Hospital Orange County, Orange, California, United States

🇺🇸

Helen De Vos, Grand Rapids, Michigan, United States

🇺🇸

University of Alabama, Birmingham, Alabama, United States

and more 3 locations

Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

First Posted Date
2018-10-18
Last Posted Date
2022-04-18
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
462
Registration Number
NCT03711305
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

🇨🇳

Jilin Cancer Hospital, Jilin, Changchun, China

A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC

First Posted Date
2018-10-09
Last Posted Date
2019-11-29
Lead Sponsor
The First Affiliated Hospital of Guangzhou Medical University
Target Recruit Count
60
Registration Number
NCT03700359
Locations
🇨🇳

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm)

First Posted Date
2018-09-13
Last Posted Date
2018-09-13
Lead Sponsor
Assistance Publique Hopitaux De Marseille
Target Recruit Count
110
Registration Number
NCT03669783

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

First Posted Date
2018-08-22
Last Posted Date
2023-11-29
Lead Sponsor
Martin Schrappe
Target Recruit Count
5000
Registration Number
NCT03643276
Locations
🇮🇹

AOUC Policlinico Bari, Bari, Italy

🇮🇹

A.O. Papa Giovanni XXIII, Bergamo, Italy

🇮🇹

S.O. Annunziata - A. O. Cosenza, Cosenza, Italy

and more 111 locations

Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors

First Posted Date
2018-08-14
Last Posted Date
2018-09-19
Lead Sponsor
Samsung Medical Center
Target Recruit Count
46
Registration Number
NCT03628131
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients

First Posted Date
2018-08-06
Last Posted Date
2018-09-04
Lead Sponsor
Peking University
Target Recruit Count
114
Registration Number
NCT03617432
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, China

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

First Posted Date
2018-07-19
Last Posted Date
2024-04-05
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
23
Registration Number
NCT03591510
Locations
🇹🇷

Novartis Investigative Site, Istanbul, Turkey

Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

First Posted Date
2018-07-16
Last Posted Date
2024-10-29
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
18
Registration Number
NCT03586999
Locations
🇺🇸

City of Hope Cancer Center, Duarte, California, United States

🇺🇸

University of Colorado Hospital, Aurora, Colorado, United States

🇺🇸

Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

First Posted Date
2018-07-11
Last Posted Date
2024-10-15
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
240
Registration Number
NCT03583710
Locations
🇸🇪

Sahlgrenska University Hospital, Gothenburg, Sweden

🇸🇪

Karolinska University Hospital, Stockholm, Sweden

🇸🇪

Akademiska Sjukhuset, Uppsala, Sweden

and more 5 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy